Report cover image

Global Brucellosis Vaccine Market Size study, by Application (Sheep, Cattle, Goat), by Type (RB51 Vaccine, S19 Vaccine, B19 Vaccine), by Distribution Channel and Regional Forecasts 2022-2032

Publisher Bizwit Research & Consulting
Published May 25, 2025
Length 285 Pages
SKU # BIZW20048106

Description

The Global Brucellosis Vaccine Market is valued at approximately USD 0.24 billion in 2023 and is expected to expand at a steady CAGR of 4.59% over the forecast period 2024-2032. Brucellosis, a contagious zoonotic disease with profound economic implications in livestock production, has necessitated consistent and widespread vaccination initiatives globally. The disease primarily afflicts cattle, sheep, and goats, causing reproductive failures and productivity losses. Brucellosis vaccines, notably live attenuated strains like RB51 and S19, play a pivotal role in disease eradication campaigns and biosecurity frameworks. With a growing awareness of zoonotic transmission risks and the need for sustainable livestock health, government-backed veterinary health programs are actively bolstering demand for effective brucellosis immunization solutions.

The rising global emphasis on food safety, public health, and livestock trade compliance is driving the adoption of vaccination strategies against brucellosis. National eradication efforts in countries with endemic prevalence, such as India, Brazil, and parts of Africa, are catalyzing market growth through policy-mandated immunization drives. Additionally, the agricultural sector's transition toward preventive healthcare, especially in commercial dairy and meat production, is creating sustained demand for brucellosis vaccines across both developed and developing economies. However, logistical challenges in cold chain maintenance, vaccine access in remote regions, and occasional resistance from unorganized farming communities remain hurdles to seamless market expansion.

Manufacturers are innovating around vaccine formulations to enhance thermal stability, improve safety profiles, and reduce the risk of post-vaccination complications. Technological advancements are also streamlining the traceability of livestock vaccination records, ensuring better compliance with international trade norms. With the emergence of combination vaccines and species-specific immunization protocols, product diversification is reshaping the competitive landscape. Furthermore, increased collaboration between public institutions and private veterinary pharmaceutical companies is augmenting research initiatives and distribution networks—especially in regions with high brucellosis incidence rates.

Geographically, North America maintains a significant footprint in the brucellosis vaccine market, supported by sophisticated livestock management systems, stringent animal health regulations, and robust veterinary infrastructure. Europe closely trails, with extensive disease control mandates and research funding. Meanwhile, Asia Pacific is anticipated to witness the fastest growth rate owing to the sheer scale of its livestock population, expanding veterinary outreach, and intensifying government-led disease eradication programs. Latin America and the Middle East & Africa present promising growth potential, driven by increasing awareness, improving agricultural productivity initiatives, and rising investments in animal health services.

Major market player included in this report are:
• Indian Immunologicals Ltd.
• Colorado Serum Company
• Boehringer Ingelheim
• Hester Biosciences
• CZ Veterinaria
• Bioveta
• Zoetis Inc.
• Merck Animal Health
• Ceva Santé Animale
• Vaxxinova
• Elanco Animal Health
• Bimeda Animal Health
• Virbac
• AVImark
• Phibro Animal Health Corporation

The detailed segments and sub-segment of the market are explained below:

By Application
• Sheep
• Cattle
• Goat

By Type
• RB51 Vaccine
• S19 Vaccine
• B19 Vaccine

By Distribution Channel
• Veterinary Hospitals
• Veterinary Clinics
• Government Agencies
• Online Pharmacies

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Table of Contents

285 Pages
Chapter 1. Global Brucellosis Vaccine Market Executive Summary
1.1. Global Brucellosis Vaccine Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Application
1.3.2. By Type
1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Brucellosis Vaccine Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Producer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Stakeholder Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Brucellosis Vaccine Market Dynamics
3.1. Market Drivers
3.1.1. Government-backed Eradication Programs
3.1.2. Rising Focus on Food Safety and Zoonotic Risk Mitigation
3.1.3. Preventive Veterinary Healthcare Adoption
3.2. Market Challenges
3.2.1. Cold Chain and Logistical Constraints
3.2.2. Limited Access in Remote and Small-holder Farms
3.2.3. Vaccine Hesitancy in Unorganized Livestock Sectors
3.3. Market Opportunities
3.3.1. Development of Thermostable and Combination Vaccines
3.3.2. Digital Traceability and Record-keeping Solutions
3.3.3. Public–Private Partnerships to Expand Outreach
Chapter 4. Global Brucellosis Vaccine Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Brucellosis Vaccine Market Size & Forecasts by Application 2022-2032
5.1. Segment Dashboard
5.2. Revenue Trend Analysis by Application, 2022 & 2032 (USD Million)
5.2.1. Sheep
5.2.2. Cattle
5.2.3. Goat
Chapter 6. Global Brucellosis Vaccine Market Size & Forecasts by Type 2022-2032
6.1. Segment Dashboard
6.2. Revenue Trend Analysis by Type, 2022 & 2032 (USD Million)
6.2.1. RB51 Vaccine
6.2.2. S19 Vaccine
6.2.3. B19 Vaccine
Chapter 7. Global Brucellosis Vaccine Market Size & Forecasts by Distribution Channel 2022-2032
7.1. Segment Dashboard
7.2. Revenue Trend Analysis by Distribution Channel, 2022 & 2032 (USD Million)
7.2.1. Veterinary Hospitals
7.2.2. Veterinary Clinics
7.2.3. Government Agencies
7.2.4. Online Pharmacies
Chapter 8. Global Brucellosis Vaccine Market Size & Forecasts by Region 2022-2032
8.1. North America Market
8.1.1. U.S. Market
8.1.1.1. Application breakdown, 2022-2032
8.1.1.2. Type breakdown, 2022-2032
8.1.2. Canada Market
8.2. Europe Market
8.2.1. U.K. Market
8.2.2. Germany Market
8.2.3. France Market
8.2.4. Spain Market
8.2.5. Italy Market
8.2.6. Rest of Europe Market
8.3. Asia Pacific Market
8.3.1. China Market
8.3.2. India Market
8.3.3. Japan Market
8.3.4. Australia Market
8.3.5. South Korea Market
8.3.6. Rest of APAC Market
8.4. Latin America Market
8.4.1. Brazil Market
8.4.2. Mexico Market
8.4.3. Rest of Latin America Market
8.5. Middle East & Africa Market
8.5.1. Saudi Arabia Market
8.5.2. South Africa Market
8.5.3. Rest of MEA Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Indian Immunologicals Ltd.
9.1.2. Colorado Serum Company
9.1.3. Boehringer Ingelheim
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Indian Immunologicals Ltd.
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Colorado Serum Company
9.3.3. Boehringer Ingelheim
9.3.4. Hester Biosciences
9.3.5. CZ Veterinaria
9.3.6. Bioveta
9.3.7. Zoetis Inc.
9.3.8. Merck Animal Health
9.3.9. Ceva Santé Animale
9.3.10. Vaxxinova
9.3.11. Elanco Animal Health
9.3.12. Bimeda Animal Health
9.3.13. Virbac
9.3.14. AVImark
9.3.15. Phibro Animal Health Corporation
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
List of Tables
TABLE 1. Global Brucellosis Vaccine market, report scope
TABLE 2. Global Brucellosis Vaccine estimates & forecasts by Region 2022-2032 (USD Million/Billion)
TABLE 3. Global Brucellosis Vaccine estimates & forecasts by Application 2022-2032 (USD Million/Billion)
TABLE 4. Global Brucellosis Vaccine estimates & forecasts by Type 2022-2032 (USD Million/Billion)
TABLE 5. Global Brucellosis Vaccine estimates & forecasts by Distribution Channel 2022-2032 (USD Million/Billion)
TABLE 6. Global Brucellosis Vaccine by segment, estimates & forecasts, 2022-2032 (USD Million/Billion)
TABLE 7. Global Brucellosis Vaccine by region, estimates & forecasts, 2022-2032 (USD Million/Billion)
TABLE 8. U.S. Brucellosis Vaccine market estimates & forecasts, 2022-2032 (USD Million/Billion)
TABLE 9. U.S. Brucellosis Vaccine market estimates & forecasts by segment 2022-2032 (USD Million/Billion)
TABLE 10. Canada Brucellosis Vaccine market estimates & forecasts, 2022-2032 (USD Million/Billion)
TABLE 11. Canada Brucellosis Vaccine market estimates & forecasts by segment 2022-2032 (USD Million/Billion)
TABLE 12. Europe Brucellosis Vaccine market estimates & forecasts, 2022-2032 (USD Million/Billion)
TABLE 13. Asia Pacific Brucellosis Vaccine market estimates & forecasts, 2022-2032 (USD Million/Billion)
TABLE 14. Latin America Brucellosis Vaccine market estimates & forecasts, 2022-2032 (USD Million/Billion)
TABLE 15. Middle East & Africa Brucellosis Vaccine market estimates & forecasts, 2022-2032 (USD Million/Billion)
TABLE 16. Global Brucellosis Vaccine demand side analysis
TABLE 17. Global Brucellosis Vaccine supply side analysis
TABLE 18. Global Brucellosis Vaccine price trend analysis
TABLE 19. Global Brucellosis Vaccine manufacturer market share, 2023
TABLE 20. Global Brucellosis Vaccine patent landscape
List of Figures
FIGURE 1. Global Brucellosis Vaccine market, research methodology
FIGURE 2. Global Brucellosis Vaccine market, market estimation techniques
FIGURE 3. Global market size estimates & forecast methods
FIGURE 4. Global Brucellosis Vaccine market, key trends 2023
FIGURE 5. Global Brucellosis Vaccine market, growth prospects 2022-2032
FIGURE 6. Global Brucellosis Vaccine market, Porter’s 5 force model
FIGURE 7. Global Brucellosis Vaccine market, PESTEL analysis
FIGURE 8. Global Brucellosis Vaccine market, value chain analysis
FIGURE 9. Global Brucellosis Vaccine market by Application, 2022 & 2032
FIGURE 10. Global Brucellosis Vaccine market by Type, 2022 & 2032
FIGURE 11. Global Brucellosis Vaccine market by Distribution Channel, 2022 & 2032
FIGURE 12. Global Brucellosis Vaccine market, regional snapshot 2022 & 2032
FIGURE 13. North America Brucellosis Vaccine market 2022 & 2032
FIGURE 14. Europe Brucellosis Vaccine market 2022 & 2032
FIGURE 15. Asia Pacific Brucellosis Vaccine market 2022 & 2032
FIGURE 16. Latin America Brucellosis Vaccine market 2022 & 2032
FIGURE 17. Middle East & Africa Brucellosis Vaccine market 2022 & 2032
FIGURE 18. Global Brucellosis Vaccine competitive landscape
FIGURE 19. Global Brucellosis Vaccine R&D pipeline overview
FIGURE 20. Global Brucellosis Vaccine market share analysis (2023)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us